Craig-Hallum raised the firm’s price target on Xeris Biopharma (XERS) to $6.50 from $5 and keeps a Buy rating on the shares following strong Q4 results, and very strong 2025 guidance. The company ended 2024 with a 35% year-over-year growth quarter, its strongest of the year, the firm notes. FY25 revenue guidance of $255M-$275M came in well ahead of Street expectations of $239.8M, representing 30% growth at the midpoint.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Biopharma price target raised to $4 from $3 at Piper Sandler
- Xeris Pharmaceuticals: Strong Growth Potential and Financial Stability Justify Buy Rating
- Xeris Biopharma price target raised to $8 from $6.60 at H.C. Wainwright
- Xeris Biopharma Reports Record Revenue and Strong 2025 Outlook
- Xeris Biopharma files $250M mixed securities shelf
Questions or Comments about the article? Write to editor@tipranks.com